Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology. Read more.
Collections open for submissions
- Latest updates from major conferences
- First-ever clinical trials
- How we treat
- New developments in delivery technology, materials, and molecular engineering for drug discovery
Latest updates from major conferences
This Journal of Hematology & Oncology and Experimental Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference.
First-ever clinical trials
This series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.
How we treat
This series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders. All submissions need to be pre-approved. Prospective authors should contact the Editorial Office at Aoife.Buckley@springernature.com with an outline of their paper, the lead author name, and institution.
Manuscripts sponsored by pharmaceutical companies will not be considered.
New developments in delivery technology, materials, and molecular engineering for drug discovery
This series covers new technology, materials, and models for drug discovery. Development and applications of organoids, 3D cultures, PDX modes, nano-molecules, AI technology, and single-cell maps for drug discovery will be the focus.
Aims and scope
Experimental Hematology & Oncology
Submit your research to our companion journal, Experimental Hematology & Oncology
Recent advances in targeted therapies in acute myeloid leukemia
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications
AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
The effects of β-glucan on human immune and cancer cells
The diagnosis and management of NK/T-cell lymphomas
Mechanism of action of lenalidomide in hematological malignancies
NK cell-based cancer immunotherapy: from basic biology to clinical development
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. We are proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."
Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology
Official journal of
Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
23.168 - 2-year Impact Factor (2021)
17.520 - 5-year Impact Factor (2021)
3.408 - Source Normalized Impact per Paper (SNIP)
4.241 - SCImago Journal Rank (SJR)
5 days to first decision for all manuscripts (Median)
30 days to first decision for reviewed manuscripts only (Median)
2,370,051 Downloads (2021)
3542 Altmetric mentions (2021)
On the blog
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).